PSMA-617

PSMA-617/Vipivotide tetraxetan/CAS: 1702967-37-0 is a radiolabeled monoclonal antibody that binds to the tumor antigen prostate specific membrane antigen (PSMA). It has been shown to be an effective treatment for prostate cancer, with clinical studies showing a significant decrease in tumor volume and size. This drug also had a high uptake rate of urea nitrogen into the tumour xenografts, which is indicative of its effectiveness. PSMA-617 is also useful as a diagnostic tool, as it can be used to diagnose solid tumours such as breast cancer and lung cancer. The biological properties of this drug are still unclear, but it has been shown to have anti-tumor effects when used in combination with radiation therapy.

msds of PSMA-617